دورية أكاديمية
أعرض في EDS

Decompression Surgery in Elderly Patients with Hemifacial Spasm Refractory to Botulinum Toxin.

التفاصيل البيبلوغرافية
العنوان: Decompression Surgery in Elderly Patients with Hemifacial Spasm Refractory to Botulinum Toxin.
المؤلفون: Tugend M; Department of Neurological Surgery, Columbia University Irving Medical Center, New York Presbyterian Hospital, New York, New York, USA., Ulane CM; Department of Neurology, Columbia University Irving Medical Center, New York Presbyterian Hospital, New York, New York, USA., Patel K; Department of Neurology, Columbia University Irving Medical Center, New York Presbyterian Hospital, New York, New York, USA., Sekula RF Jr; Department of Neurological Surgery, Columbia University Irving Medical Center, New York Presbyterian Hospital, New York, New York, USA.
المصدر: Movement disorders clinical practice [Mov Disord Clin Pract] 2024 Aug; Vol. 11 (8), pp. 966-972. Date of Electronic Publication: 2024 May 23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 101630279 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2330-1619 (Electronic) Linking ISSN: 23301619 NLM ISO Abbreviation: Mov Disord Clin Pract Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hoboken, NJ : Wiley, [2014]-
مواضيع طبية MeSH: Hemifacial Spasm*/surgery , Hemifacial Spasm*/drug therapy, Humans ; Female ; Male ; Aged ; Neuromuscular Agents/therapeutic use ; Neuromuscular Agents/administration & dosage ; Aged, 80 and over ; Decompression, Surgical/methods ; Decompression, Surgical/adverse effects ; Prospective Studies ; Treatment Outcome ; Botulinum Toxins/therapeutic use ; Botulinum Toxins/administration & dosage ; Botulinum Toxins, Type A/therapeutic use ; Botulinum Toxins, Type A/administration & dosage ; Facial Nerve/surgery ; Facial Nerve/drug effects ; Facial Nerve/physiopathology ; Cohort Studies ; Middle Aged
مستخلص: Background: Botulinum toxin is an effective treatment for hemifacial spasm in elderly patients. However, some patients do not tolerate the side effects and frequency of botulinum toxin treatments.
Objectives: The purpose of this study was to evaluate the characteristics and outcomes of a cohort of elderly patients referred by neurologists for surgical decompression of the facial nerve following botulinum toxin treatment.
Methods: In a prospective cohort study, logistic regression was used to detect potential predictors of spasm-freedom after surgical decompression of the facial nerve in elderly patients that received ≤8 and >8 botulinum toxin treatments for hemifacial spasm before surgery. Age, sex, side, preoperative symptom duration, and preoperative botulinum toxin treatment were assessed as potential predictors of spasm-freedom at last follow-up.
Results: Of 76 elderly patients with hemifacial spasm treated with botulinum toxin and microvascular decompression, with at least 2-years of follow-up (median, 44.5 months), 84.2% were spasm-free at last follow-up. Age (P = 0.38), sex (P = 0.59), side (P = 0.15), preoperative symptom duration (P = 0.7), and number of preoperative botulinum toxin treatments (P = 0.3) were not predictors of long-term spasm-freedom. Permanent ipsilateral hearing loss was the most frequent complication (3.9%).
Conclusion: This study provides evidence that elderly patients can undergo botulinum toxin treatment for hemifacial spasm without compromising their likelihood of achieving spasm-freedom with future surgical decompression. Therefore, surgical decompression of the facial nerve is an effective therapy for elderly patients with hemifacial spasm refractory to botulinum toxin.
(© 2024 International Parkinson and Movement Disorder Society.)
References: Lancet. 1998 Mar 21;351(9106):857-61. (PMID: 9525362)
World Neurosurg. 2020 Jul;139:e383-e390. (PMID: 32305605)
J Neurosurg. 2015 Oct;123(4):1059-64. (PMID: 26162037)
Clin Neurol Neurosurg. 2020 Aug;195:105874. (PMID: 32428796)
Clin Neurol Neurosurg. 2019 Sep;184:105417. (PMID: 31351214)
Surg Radiol Anat. 2021 Feb;43(2):291-299. (PMID: 33130978)
J Neurol Neurosurg Psychiatry. 1998 Jun;64(6):751-7. (PMID: 9647304)
Arch Neurol. 1978 Aug;35(8):481-3. (PMID: 666603)
Rev Neurol. 1999 Dec 16-31;29(12):1108-11. (PMID: 10652731)
Neurosurg Focus. 2009 Oct;27(4):E10. (PMID: 19795949)
J Thromb Haemost. 2007 Jul;5 Suppl 1:310-7. (PMID: 17635742)
J Thromb Haemost. 2007 Apr;5(4):692-9. (PMID: 17367492)
Eur Neurol. 2013;70(3-4):165-71. (PMID: 23921578)
Brain Sci. 2022 Apr 29;12(5):. (PMID: 35624968)
J Neurol. 2022 Jul;269(7):3706-3712. (PMID: 35113259)
Clin Neurol Neurosurg. 2021 Apr;203:106555. (PMID: 33662742)
Neurosurg Focus. 2013 Mar;34(3):E3. (PMID: 23452316)
J Neurol Surg A Cent Eur Neurosurg. 2022 Mar;83(2):118-121. (PMID: 34237777)
J Neurol Neurosurg Psychiatry. 1986 Jul;49(7):827-9. (PMID: 3746313)
Acta Neurochir (Wien). 2020 Nov;162(11):2801-2809. (PMID: 32930877)
J Korean Neurosurg Soc. 2010 Jun;47(6):442-5. (PMID: 20617090)
Muscle Nerve. 2013 Nov;48(5):770-6. (PMID: 24000070)
J Neurosurg. 2018 Jan;128(1):193-201. (PMID: 28186450)
J Korean Med Sci. 1993 Oct;8(5):334-40. (PMID: 8305141)
J Neurol Sci. 2023 Mar 15;446:120587. (PMID: 36804510)
Arch Neurol. 2006 Mar;63(3):441-4. (PMID: 16533973)
Neurochirurgie. 2018 May;64(2):94-100. (PMID: 29680283)
Arch Neurol. 2002 Mar;59(3):418-20. (PMID: 11890846)
Neurology. 2007 Jul 24;69(4):402-4. (PMID: 17646635)
Medicine (Baltimore). 2021 Jun 25;100(25):e26481. (PMID: 34160460)
Neurology. 1984 Jul;34(7):891-7. (PMID: 6330612)
Turk J Med Sci. 2019 Oct 27;49(6):1721-1726. (PMID: 31655522)
فهرسة مساهمة: Keywords: botox; botulinum toxin; elderly; hemifacial spasm; microvascular decompression; treatment refractory
المشرفين على المادة: 0 (Neuromuscular Agents)
EC 3.4.24.69 (Botulinum Toxins)
EC 3.4.24.69 (Botulinum Toxins, Type A)
تواريخ الأحداث: Date Created: 20240523 Date Completed: 20240817 Latest Revision: 20240819
رمز التحديث: 20240819
مُعرف محوري في PubMed: PMC11329574
DOI: 10.1002/mdc3.14064
PMID: 38779725
قاعدة البيانات: MEDLINE
الوصف
تدمد:2330-1619
DOI:10.1002/mdc3.14064